Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Nurix Therapeutics (NASDAQ:NRIX) had its price target lifted by equities researchers at Robert W. Baird from $33.00 to $36.00 in a research note issued on Tuesday, MarketBeat Ratings reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 52.09% from the stock’s current price.

A number of other research analysts also recently weighed in on NRIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. HC Wainwright increased their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, August 4th. Royal Bank Of Canada lifted their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Finally, BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $23.67 on Tuesday. Nurix Therapeutics has a 1 year low of $9.18 and a 1 year high of $28.23. The stock has a market capitalization of $2.46 billion, a P/E ratio of 10.25 and a beta of 1.82. The company’s 50-day moving average is $25.14 and its 200 day moving average is $21.06.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Monday, October 12th. The company reported $4.73 EPS for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%. The business had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. Research analysts anticipate that Nurix Therapeutics will post -2.69 earnings per share for the current year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,356 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the sale, the insider owned 117,227 shares in the company, valued at approximately $2,930,675. This represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia P. Gregory sold 22,583 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total transaction of $528,442.20. Following the completion of the sale, the director owned 10,750 shares in the company, valued at approximately $251,550. This trade represents a 67.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 43,955 shares of company stock valued at $1,046,906 in the last three months. Company insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Nurix Therapeutics during the 2nd quarter valued at about $212,769,000. General Atlantic L.P. purchased a new position in Nurix Therapeutics in the fourth quarter worth about $92,899,000. Perceptive Advisors LLC lifted its stake in shares of Nurix Therapeutics by 151.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock worth $67,455,000 after buying an additional 2,139,728 shares in the last quarter. Trails Edge Capital Partners LP bought a new position in shares of Nurix Therapeutics in the second quarter worth approximately $38,166,318. Finally, Bank of America Corp DE bought a new position in shares of Nurix Therapeutics in the second quarter worth approximately $20,429,000.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analysts remain constructive on Nurix’s outlook. Robert W. Baird raised its price target to $36 and maintained an “outperform” rating, while Needham reaffirmed a “buy” rating with a $34 target. Truist kept a “buy” rating despite trimming its target to $33. These targets imply substantial potential upside from recent trading levels. Nurix Therapeutics Q3 2026 Earnings
• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 study of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst reiterated a “Strong Buy,” citing promising Phase 1/2 data, possible accelerated approval, partnerships and multiple development pathways. Nurix Strong Buy Analysis
• Positive Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, supporting the view that the stock’s valuation does not fully reflect its pipeline and commercial potential. RBC Capital Markets Valuation Commentary
• Neutral Sentiment: Nurix reported quarterly earnings well above consensus, largely reflecting unusually high revenue compared with estimates. However, the earnings reaction was pressured by rising operating expenses, highlighting continued investment needs for its clinical programs. Nurix Q3 Earnings and Operating Expenses
• Negative Sentiment: Director Julia P. Gregory sold 22,583 shares for approximately $528,000, reducing her direct holdings by 67.75%. Although insider sales can be made for personal or diversification reasons, the transaction may weigh modestly on sentiment. SEC Insider Trading Filing
• Negative Sentiment: Nurix faces execution and financial risks from its reliance on Roche for bexobrutideg, including cost burdens, reduced control and uncertain future returns. Nurix Roche Reliance Risk Analysis

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.